Panbela Therapeutics, Inc. · OTC:PBLA
Panbela Therapeutics — Sun BioPharma — Investor Presentation (December 2017)
28 slides from Panbela Therapeutics's investor presentation, Dec 4, 2017
Slide 1: Disruptive Therapeutics for Pancreatic Diseases: Corporate Overview
4 S: iN Disruptive Therapeutics a BioPHarma for Pancreatic Diseases " Corporate Overview | December 4,2017 | Ticker: SNBP
Slide 2: Forward Looking Statements Disclaimer
Forward Looking Statements Disclaimer Certain statements in this presentation are forward-looking statements within the meaning of the P. Litigation Reform Act of 1995 and are provided under the protection of the safe harbor for forward-looking statements provided by that Act. Forward-looking statem
Slide 3: Executive Management Team
Executive Management Team Michael T. Cullen, MD, MBA | Co-Founder and Executive Chairman MGI Pharma, GD Searle, SunPharm, Omnicare, 3M David B. Kaysen | CEO & Director Uroplasty, Rehabilicare, Diametrics Medical Scott Kellen | vp of Finance & CFO Kips Bay Medical, Transoma Medical, ev3 Inc., Deloitt
Slide 4: Our Mission: Disruptive Therapeutics
Our Mission: Disruptive Therapeutics Sun BioPharma Inc. is a clinical stage biopharmaceutical company developing disruptive therapeutics for pancreatic disease. Our Focus: Pancreas s are aimed at pancreas, including chronic and ‘eatitis. Ce iad eee Our Technology: SBP-101 SBP-101 is an originally. t
Slide 5: SBP-101 Highlights
SBP-101 Highlights 2 a Urgent Leverage Minimizes Phase 1a Early Signals Unmet Needs _ Natural Process Toxicity Complete of Efficacy Pancreatic ductal SBP-101, a small Natural selectivity Completed patient Early signals of adenocarcinoma (PDA) — molecule polyamine achieves targeted enrollment in Phas
Slide 6: SBP-101 Programs
SBP-101 Programs PARTNERS us Mayo Clinic Honor Health Australia Adelaide Cancer Centre Austin Health (Olivia Newton John Cancer Centre) University Of Minnesota Cedars Sinai DISCOVERY NON-CLINICAL CLINICALTRIALS (QENEEEII |cronic&: Recurrent Acute Pancreatitis Active Partners in US and Australia Sun
Slide 7: SBP-101 Timeline
SBP-101 Timeline DISCOVERY 2011-2014 Company founded Technology licensed from the University of Florida Q3: US Orphan Drug Status granted NON-CLINICAL 2015 2016 FDAIND Q1: First patient accepted for began dosing Phase 1 study Four centers Australian recruited HREC/TGA patients (2 USA, accepted CTN 2
Slide 8: Market Opportunity
Slide 9: Pancreatic Cancer — Third Leading Cause of Death in US
Pancreatic Cancer — Third Leading Cause of Death in US Top Five Cancer Deaths USA 2016 TYPE INCIDENCE* DEATHS* 5-YEAR SURVIVAL” Lung 224,390 158,080 17.7% Colon 134,490 49,190 65.1% Pancreas Breast 246,660 Prostate 180,890 26,120 98.9% *Estimates for 2016 based upon 2009-2013 data (Source: http://se
Slide 10: Pancreatic Cancer
Pancreatic Cancer Pancreatic Cancer US 53,000 cases/year O) HIGH MORTALITY AND SHORT LIFE EXPECTANCY @ > commonrvee | PDA 95% pancreatic ductal adenocarcinoma (PDA) © LOW SURVIVAL RATE + 7.7% 5-year survival rate + <3 years for metastatic disease © CURRENT Rx MINIMAL EFFICACY = APPROVAL Current Rx’s
Slide 11: Unmet Medical Need: Pancreatitis
Unmet Medical Need: Pancreatitis Pancreatitis US 330,000 cases/year ACUTE 300,000 US hospitalizations/year RECURRENT ACUTE ~50% Of Acute Admissions CHRONIC 30,000 US Hospitalizations/year DIRECT ANNUAL COST OF “$3 BILLION GeO 8 © © 2-5% MORTALITY RATE Source Data: Afghani, Pandol, et al Pancreas, No
Slide 12: SBP-101
SBP-101
Slide 13: Unique Mechanism of Action SBP-101: Polyamine Metabolic Inhibitor
Unique Mechanism of Action SBP-101: Polyamine Metabolic Inhibitor (PMI) > > SBP-101 is an analog of a naturally occurring polyamine (PA) SBP-101, like natural PAs, is taken up by cells Uptake of PAs is accelerated in pancreatic ductal adenocarcinoma (PDA) cells SBP-101 in PDA cells disrupts normal p
Slide 14: Third Generation of Polyamines
Third Generation of Polyamines (Professor Bergeron — Univ of Florida) ew oe oe Cd POPP IHPPOAPP TA SBP-101 Diethyldihydroxy-homospermine Chee he Diethylhomospermine Tested as an anti- diarrhreal in AIDS (early 1990s, investigator sponsored IND) Currently In Human Study for PDA by Sun BioPharma OPAPP
Slide 15: Phase 1 Trial & Non-Clinical
PHASE 1 TRIAL& NON- CLINICAL
Slide 16: Preliminary Efficacy Results — Phase 1a Dose Escalation Study
] Preliminary Efficacy Results — Phase 1a Dose Escalation Study Preliminary Efficacy 24/29 patients were evaluable for preliminary signals of efficacy at 8 weeks Stable Disease 8/24 had Stable Disease (SD, RECIST criteria) Reduction in CA 19-9 11/28 patients (39%) had at least one reduction in CA 19
Slide 17: Preliminary Efficacy Results — Phase 1a Dose Escalation Study
] Preliminary Efficacy Results — Phase 1a Dose Escalation Study 13 patients Total Cumulative Doses between 2.5 and 8.0 mg/kg Best Responses at Stable Disease 8 wee ks 5/12 had Stable Disease (SD, RECIST criteria) > Reduction in CA 19-9 5/13 patients had at least one reduction in CA 19-9 rd Median Su
Slide 18: Preliminary Safety Results — Phase 1a Dose Escalation Study
Preliminary Safety Results — Phase 1a Dose Escalation Study & al * Safe & well + Recommended No bone marrow No neuropathy tolerated dose dose for suppression (painful nerve recommended for continued (ability to resist damage) next clinical trial development infection) * DSMB supports < Eaewar moving
Slide 19: Next Study is an Unblinded, First-Line Phase 1a/1b
] Next Study is an Unblinded, First-Line Phasela/1b > Triple combination with nab-paclitaxel, gemcitabine and SBP-101 > Previously untreated patients with metastatic pancreatic ductal adenocarcinoma > Dose-escalation phase, three cohorts to treat 12- 18 patients (1a) > Expansion phase to treat 10 ad
Slide 20: SBP-101 in Pancreatic Cancer: Strong Combination Rationale
SBP-101 in Pancreatic Cancer: Strong Combination Rationale i\ ae we Superior Efficacy Aaitive ‘Efficacy < * Preclinical studies show additive efficacy in combination with gemcitabine and/or nab- paclitaxel combination * Preclinical studies show superior efficacy of SBP-101 * Compelling pre- clinical
Slide 21: SBP-101 vs. Gemcitabine & Nab-paclitaxel Combinations
] SBP-101 vs. Gemcitabine & Nab-paclitaxel Combinations 100 Maximum % ° growth inhibition a (meantSE) at 96 70 hours with 10 uM 5 0 SBP-101 alone and ag in combination z é with gemcitabine and/or nab- %, paclitaxel in 6 20 human pancreatic 10 cancer cell lines © AsPea BPS CoP ant HPAFAIL MiaPaca-2 P
Slide 22: SBP-101 + Gemcitabine & Nab-paclitaxel - BxPC-3 Xenografts
] SBP-101 + Gemcitabine & Nab-paclitaxel - BxPC-3 Xenografts SBP-101 Improved TGI and Response Rates TUMOUR TREATMENT. GROWTH COMPLETE RESPONSE PARTIAL RESPONSE INHIBITION SBP-101 79% ie} ie} SBP-101 + Gem 93% ie} 20% SBP-101 + nab-p 98% 40% 60% SBP-101 + Gem + nab-p 97% 10% 30% Gem + nab-p 94% 0 50
Slide 23: Intellectual Property
Intellectual Property Issued Patent: > US Patent No 6,160,002 is a method of use patent that covers the use of SBP-101 for the chemical resection of the exocrine portion of the pancreas, issued on December 12, 2000, expiring on July 19, 2019 (licensed from the University of Florida). Patents Pending
Slide 24: Physician Collaborators
Physician Collaborators © 9 94 Dan Von Hoff, M.D. James Abbruzzese,M.D. David Goldstein, M.D Ashok Saluja, Ph.D. Steve Pandol, M.D. TGen/Mayo Clinic, Duke Cancer Institute, Prince Henry & Prince of Laboratory U of Miami, Laboratory Cedars“ Scottsdale, AZ Durham, NC Wales Hospital, Sydney, formerly U
Slide 25: Institutional Collaborators
] Institutional Collaborators UNIVERSITY BK Giyy OPMIAML UNIVERSITY of Research Partners aiceze ee ea ED cenars SINAL uU UF FLORIDA MAYO Clinical Sites CLINIC UNIVERSITY of US Gy | HONORHEALTH| UF (FLORIDA Sees ili Wa lw. Clinical Sites ep Newton-John NSW Australia _ ons teeta ict World Renowned Res
Slide 26: Milestones — PDA & Pancreatitis
Milestones — PDA & Pancreatitis ory 2018 2018 aes irae First-Line Trial Early Results Identified safe & Mabe . Initiation of patient Early results from well tolerated dose : aay ye enrollment in Q first-line cancer Phasejla cancer, second cancer trial trial 03/04 safety data available Pancreatic Can
Slide 27: Capitalization: As of September 30, 2017
Capitalization: As of September 30, 2017 % of Fully Diluted Capitalization Table $ Value ‘Common Shares Outstanding 3,670,432 Mandatorily Convertible Notes * 313,134 $10.10 $3,162,648 Stock Options 683,960 $9.77 $6,684,575 Warrants 351,500 $5.93 $2,084,063 Fully Diluted Shares Outstanding 5,019,026
Slide 28: Disruptive Therapeutics for Pancreatic Diseases
4 S: iN Disruptive Therapeutics 7%, BIOPHARMA for Pancreatic Diseases
Sun BioPharma — Investor Presentation (December 2017) on 6ix